Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox in Beta-thalassemia and Transfusional Hemosiderosis
NCT00171171Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2004
- Primary completion
- Nov 2006
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of deferasirox in transfusion hemosiderosis, sponsored by Novartis. Primary endpoint: Liver Iron Concentration at 1 year. Started May 2004; status: completed.
02
Drugs
deferasirox
03
Conditions
transfusion hemosiderosis
Beyond the preview
Go deeper on NCT00171171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171171.